Related Experiment Video
Updated: Apr 21, 2026
06:15
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
2.0K
Epitheloid hemangioma treated with naproxen sodium
Elie Nasr1, Mary Roz Timbang, Lena Naffaa
1From the *Department of Plastic Surgery, Institute of Dermatology and Plastic Surgery, Cleveland Clinic, Cleveland, OH; and †Department of Radiology, Akron Children Hospital, Akron, OH.
The Journal of Craniofacial Surgery
|November 8, 2014
Summary
Epithelioid hemangioma (EH) is a rare vascular tumor. This case report details the successful regression of scrotal EH in a young male using naproxen sodium, a novel treatment approach.
Area of Science:
- Vascular Oncology
- Dermatopathology
- Pediatric Oncology
Background:
- Epithelioid hemangioma (EH) is a rare vascular tumor, typically affecting the head and neck.
- Scrotal EH is exceptionally rare, with fewer than 30 reported cases.
- Established treatments for EH include surgery, steroids, radiotherapy, and chemotherapy, with varying anecdotal success.
Observation:
- A 14-year-old male presented with scrotal epithelioid hemangioma.
- The patient was treated with naproxen sodium.
- Complete regression of the scrotal EH was observed following naproxen sodium treatment.
Findings:
- Naproxen sodium induced complete regression of scrotal epithelioid hemangioma.
- This represents the first documented case of scrotal EH regression with naproxen sodium.
- The efficacy of naproxen sodium as a non-invasive treatment for scrotal EH is demonstrated.
Implications:
- Naproxen sodium may offer a novel, non-surgical therapeutic option for scrotal epithelioid hemangioma.
- This finding warrants further investigation into the role of non-steroidal anti-inflammatory drugs (NSAIDs) in treating vascular tumors.
- Highlights the potential for alternative treatments in rare oncological presentations.
Related Concept Videos
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K
01:24Nephrotic Syndrome III : Nursing Management
519
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
519
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
628
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
628
01:26Nephrotic Syndrome II : Assessment and Medical Management
387
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
387
01:30Epistaxis
815
Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
815
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
673
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
673